Anti-CD137 Antibody and PD-1 Inhibitor Combination for Solid Tumors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies using CD137 antibodies face limitations, including hepatotoxicity and limited clinical efficacy, and there is a need for improved treatments that effectively target solid tumors.
Innovation Solution
A combination therapy comprising an anti-CD137 antibody or antigen-binding fragment and a PD-1 inhibitor, which works by specifically binding to CD137 and utilizing a PD-1 inhibitor to enhance anti-tumor immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CD137 antibody therapy is used to activate immune cells and enhance anti-tumor immunity, then anti-tumor immune response is improved, but hepatotoxicity occurs
Solution Approach 1:
The patent combines CD137 antibody therapy with PD-1 inhibitor treatment to create a synergistic combination therapy. This merging of two immunotherapeutic approaches enhances anti-tumor immunity through multiple mechanisms: CD137 activation boosts T cell and NK cell function, while PD-1 inhibition removes suppressive checkpoints. The combination achieves superior anti-tumor efficacy compared to either monotherapy, while the patent addresses hepatotoxicity concerns through optimized dosing regimens and selection of CD137 antibodies with favorable safety profiles.
2Productivity
If higher doses of CD137 antibody are administered to improve therapeutic effect, then anti-tumor efficacy is enhanced, but hepatotoxicity increases
Solution Approach 1:
The patent optimizes dosing parameters by establishing specific dose ranges and administration schedules for the combination therapy. Rather than simply increasing CD137 antibody dose, the patent fine-tunes the dosing of both CD137 antibody and PD-1 inhibitor to achieve synergistic efficacy while maintaining safety. This includes determining optimal dose ratios, administration intervals, and sequence of administration to maximize anti-tumor effect while minimizing hepatotoxicity.
3Ease of operation
If CD137 antibody is used as monotherapy, then treatment simplicity is maintained, but clinical efficacy is limited
Solution Approach 1:
The patent merges CD137 antibody therapy with PD-1 inhibitor treatment to overcome the limited efficacy of monotherapy. This combination leverages two complementary immunotherapeutic mechanisms: CD137 activation enhances immune cell proliferation and cytokine production, while PD-1 blockade prevents T cell exhaustion and maintains immune response. The synergistic interaction between these two agents produces enhanced anti-tumor efficacy that exceeds the sum of individual therapies, addressing the efficacy limitation of CD137 monotherapy.
Data Source
AI summary
The present invention relates to combination therapies for treating cancer in a subject, as well as methods for use thereof. The combination therapies comprise (a) an antibody, or antigen-binding fragment thereof, that specifically binds to CD137 and (b) a further immunotherapeutic agent, wherein the further immunotherapeutic agent is a PD-1 inhibitor. The invention also relates to pharmaceutical compositions comprising, uses of, methods of using, and kits comprising the combination therapies of the invention. The cancer may be a solid tumour.